Analysis of over 11,000 participants in the SUSTAIN and PIONEER trials revealed that gastrointestinal disorders were the predominant adverse effects, occurring in approximately 39-42% of semaglutide users compared to 22-25% of those receiving comparators
F., Burgard, P., and Kolker, S
View Full Study Creating the amylin story
Relevant in vivo and in vitro experiments have confirmed that IGFBP-L1 methylation exerts a pro-oncogenic effect by promoting PI3K/AKT phosphorylation and IGFBP-L1 methylation has become a potential marker for the early detection of esophageal cancer, as well as a predictive marker for PI3K-targeted therapy in esophageal cancer (85)
Ethics declarations Competing interests Y.C.S
By maintaining healthy NGF levels, ALCAR mitigates neuronal decay and supports the brain's innate ability to heal and rewire itself